Hematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection. - Wikidata - awgldk - TriplyDB

Hematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection.

Hematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection.

http://www.wikidata.org/entity/Q33400777

about

The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection.Treatment of acute hepatitis C in breast cancer patient: a case report.

P2860

Q41732527-EE99DFA3-4BD6-4CEB-837B-AA089F7F1C6E Q42232094-1640798E-6241-472C-8C35-5C34DB9F722A

P2860

Hematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection.

http://www.wikidata.org/entity/Q33400777

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Hematologic safety of breast c ...... atitis B or C virus infection.

@ast

Hematologic safety of breast c ...... atitis B or C virus infection.

@en

type

label

Hematologic safety of breast c ...... atitis B or C virus infection.

@ast

Hematologic safety of breast c ...... atitis B or C virus infection.

@en

prefLabel

Hematologic safety of breast c ...... atitis B or C virus infection.

@ast

Hematologic safety of breast c ...... atitis B or C virus infection.

@en

P1433

Q33400777-6FAB582E-86B3-44D8-81EF-189A66A3D2A5

P1476

Q33400777-9C52949B-34FA-4D89-979C-D4D9BBBAFCA1

P2093

Q33400777-06912BFD-DE5B-4A1F-A784-78E3C549111C

Q33400777-0FB95556-5647-4171-B0B6-478A12D6904C

Q33400777-19322016-9D7B-4CB8-8BD1-E098CAF7BAB4

Q33400777-1D46E159-28D3-445D-908B-DCB5E10107F5

Q33400777-402DCD86-FE1A-4728-AD2B-540A14D67A96

Q33400777-47BC2529-72EA-4D88-A3B0-6D2BA2181C6B

Q33400777-76DF9254-41E0-4B50-B2FD-021CDA52D9DD

Q33400777-95397E85-8AEC-4AA6-8570-2D77E3B9393F

Q33400777-C9A0E1A2-1845-43A5-A295-1146CB19164D

P2860

Q33400777-1983C6CB-94CA-4ED8-AC7D-F819E8880916

Q33400777-343D1A86-F221-4710-9A4D-3B9C0CB83DB5

Q33400777-3F382F1A-0103-4E6F-AF30-0FA266B08BD9

Q33400777-480E7DD9-D51B-4686-95DE-04670297027C

Q33400777-48383F66-3CC8-4A1B-9648-67B5919B49CC

Q33400777-6D0AF24B-497B-4811-8B4D-8638B7E4A54E

Q33400777-8A9700EB-65E4-418F-AE4E-94E4FE0D026A

Q33400777-92A91DBA-A23B-4269-925A-3F48A382080F

Q33400777-952460B5-1F64-4385-90AE-365CE46F3506

Q33400777-D224DEC5-5E21-4F6B-ADBF-C866392415FF

P304

Q33400777-F6FBF5DA-E043-495F-B222-FA61EC3F63B2

P31

Q33400777-E61D56B7-88DD-46DD-8590-34D712269F43

P356

Q33400777-F4DD158A-6D18-4101-95D2-4CC7D5D38B89

P433

Q33400777-E46BFF4E-F7A2-4DF2-8DD1-69624BBE4419

P478

Q33400777-21B5F9CA-8FF4-419E-90DE-ABC5B599FB4A

P577

Q33400777-40E049DB-CF85-46B9-A821-B2DB01B11C00

P698

Q33400777-43247C14-3EA2-4975-9854-982379833380

P356

P1433

P1476

Hematologic safety of breast c ...... atitis B or C virus infection.

@en

P2093

Chikako Shimizu

http://www.w3.org/2001/XMLSchema#string

Hirokazu Shoji

http://www.w3.org/2001/XMLSchema#string

Kan Yonemori

http://www.w3.org/2001/XMLSchema#string

Kenji Hashimoto

http://www.w3.org/2001/XMLSchema#string

Kenji Tamura

http://www.w3.org/2001/XMLSchema#string

Makoto Kodaira

http://www.w3.org/2001/XMLSchema#string

Masashi Ando

http://www.w3.org/2001/XMLSchema#string

Mayu Yunokawa

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Fujiwara

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Diagnosis, management, and treatment of hepatitis C

Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma.

Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis.

Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine.

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.

Hepatitis C virus infection does not preclude standard breast cancer-directed therapy.

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

P304

228-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000336904

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22508294

http://www.w3.org/2001/XMLSchema#string